CCR3 was detected in immersion fixed paraffin-embedded sections of human lymph node using 15 µg/mL Rat Anti-Human CCR3 Monoclonal Antibody (Catalog # MAB155) overnight at 4 °C. Tissue was stained with the Anti-Rat ...read more
Recombinant Human CCL11/Eotaxin (Catalog # 320‑EO) chemoattracts the BaF3 mouse proB cell line transfected with human CCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the ...read more
Clone 61828 was used by HLDA to establish CD designation
Y3 rat myeloid cell line transfected with human CCR3 Accession # P51677
Detects human CCR3 transfectants in flow cytometry. In flow cytometry, no cross-reactivity with CCR1, CCR2, CCR5, and CCR6 transfectants or the parental cell line is observed. Detects CCR3 on peripheral blood eosinophils.
Protein A or G purified from hybridoma culture supernatant
<0.10 EU per 1 μg of the antibody by the LAL method.
Test in a species/application not listed above to receive a full credit towards a future purchase.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CCR3 Antibody (61828) and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.